Lipella Pharmaceuticals I...

NASDAQ: LIPO · Real-Time Price · USD
2.44
-0.19 (-7.40%)
At close: Apr 29, 2025, 3:27 PM

Company Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.

The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. logo
Country United States
IPO Date Dec 19, 2022
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Dr. Jonathan Kaufman M.B.A., Ph.D.

Advertisement

Contact Details

Address:
7800 Susquehanna St.
Pittsburgh, Pennsylvania
United States
Website https://www.lipella.com

Stock Details

Ticker Symbol LIPO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001347242
CUSIP Number 53630L100
ISIN Number US53630L1008
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Jonathan Kaufman M.B.A., Ph.D. Co-Founder, Chairman, Chief Executive Officer, President, Secretary & Treasurer
Douglas Johnston CPA Chief Financial Officer
Dr. Michael B. Chancellor M.D. Co-Founder, Chief Medical Officer & Director
Janet Okonski Director of Clinical Operations
Katie Johnston Controller
Michele Gruber Director of Operations

Latest SEC Filings

Date Type Title
Apr 14, 2025 8-K Current Report
Apr 09, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 09, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 09, 2025 8-K Current Report
Apr 07, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 07, 2025 4 Filing
Apr 07, 2025 8-K Current Report
Apr 04, 2025 424B5 Filing
Apr 04, 2025 424B3 Filing
Apr 01, 2025 D Filing